白血病中的胸腺基质淋巴细胞生成素：一把双刃剑？

Thymic stromal lymphopoietin in leukemia: A double-edged sword?

作者信息

Zou Xing, Gu Mengmeng, Su Yue, Yao Dayong, Gang Hao, Li Yang, Shi Ce

机构信息

NHC Key Laboratory of Cell Transplantation, The First Affiliated Hospital of Harbin Medical University, Harbin, China.

Department of Urology, The First Affiliated Hospital of Harbin Medical University, Harbin, China.

出版信息

Leuk Res Rep. 2025 Jul 23;24:100530. doi: 10.1016/j.lrr.2025.100530. eCollection 2025.

DOI:10.1016/j.lrr.2025.100530

PMID:40787610

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12332884/

Abstract

Thymic stromal lymphopoietin (TSLP) is a cytokine expressed by various cell types. It is involved in the development of allergies, autoimmune diseases, and cancers. TSLP affects immune responses and disease pathogenesis by binding to a heterodimeric receptor complex. In leukemia, particularly acute lymphoblastic leukemia (ALL), the importance of TSLP is being increasingly recognized. It has been shown that TSLP promotes leukemia proliferation by regulating different signaling pathways. However, it has also shown that other gene mutations can occur during this proliferative process, making it impossible to completely cure leukemia by targeting TSLP alone. Additionally, effect of TSLP on leukemia was found to be dose dependent. Whilst low doses were found to support the proliferation of leukemia cells, high doses were found to induce apoptosis in leukemia cells. This review focuses on the dual mechanisms of TSLP in leukemia, providing new insights for leukemia treatment.

摘要

胸腺基质淋巴细胞生成素（TSLP）是一种由多种细胞类型表达的细胞因子。它参与过敏、自身免疫性疾病和癌症的发展。TSLP通过与异二聚体受体复合物结合来影响免疫反应和疾病发病机制。在白血病，特别是急性淋巴细胞白血病（ALL）中，TSLP的重要性正日益得到认可。已经表明，TSLP通过调节不同的信号通路促进白血病增殖。然而，也已表明在此增殖过程中可能发生其他基因突变，使得仅靶向TSLP无法完全治愈白血病。此外，发现TSLP对白血病的作用是剂量依赖性的。虽然低剂量被发现可支持白血病细胞的增殖，但高剂量被发现可诱导白血病细胞凋亡。本综述重点关注TSLP在白血病中的双重机制，为白血病治疗提供新的见解。